Compare ProShares Ultra Bitcoin ETF (BITU) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs Charles River Laboratories Intl. Inc — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.16, while Charles River Laboratories Intl. Inc trades at $286.28 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | CRL | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $282.00 |
52-Week Low | $8.12 | $145.57 |
Market Cap | — | $13.46B |
Enterprise Value | — | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITU's stock trades at $9.205, down 1.34% in the last 24 hours, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company has declared several dividends in 2026, with the latest being $0.02 per share. Key support and resistance levels are tightly clustered around $9 to $10, indicating limited recent price movement.
The outlook for BITU is cautious due to bearish technical indicators and negative sentiment from financial media. Investment opportunities may exist for dividend-focused investors, but risks include potential underperformance highlighted by analysts and market volatility. The stock's proximity to support levels suggests vulnerability to further declines.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
